T HE MAJORITY of malignant tumors of the pancreas are of epithelial derivation (including endocrine carcinomas). Sarcomas and secondary tumors account for the remaining minority. Undifferentiated malignancies are generally accepted to represent probable carcinomas, making up a small percentage of all pancreatic tumors (2% to 7%). [1] [2] [3] [4] [5] [6] A variety of different subtypes of anaplastic carcinoma have been described, 7 including spindle cell, giant cell, pleomorphic giant cell, and round cell. A complete analysis of the specific clinical, histologic, immunophenotypic, molecular, treatment, and follow-up information of a large cohort of patients with anaplastic carcinoma of the pancreas is absent from the literature. Therefore, we undertook a study of 35 anaplastic carcinomas to catalogue the various characteristics in a single comprehensive study. It is the intention of this study to determine the clinical characteristics, immunophenotypic expression, cell cycle analysis, K-ras oncogene mutation pattern, and the treatment and clinical outcome for patients with different histologic subtypes of anaplastic carcinoma of the pancreas.
Materials and Methods
Thirty-five cases of anaplastic carcinoma of the pancreas were identified in the files of the Endocrine Tumor Registry at the Armed Forces Institute of Pathology from the years 1955 to 1997. These 35 cases were identified in a review of 10,655 (0.3%) benign or malignant primary pancreatic tumors seen in consultation between 1955 and 1997. The diagnoses included in our review encompassed a variety of terms for anaplastic carcinoma, including pleomorphic carcinoma, undifferentiated carcinoma, and giant cell carcinoma. Eighteen cases were obtained from civilian sources, including university medical centers and foreign contributors, nine cases from Veterans Administration Medical Centers, and eight cases from military hospitals. Materials within the Institute's files were supplemented by a review of the patient demographics, symptoms at presentation, medical history, radiographic studies, surgical pathology reports, surgical reports, and oncology data records by specific questionnaires or direct communication with the physician or the patient.
Hematoxylin-eosin-stained slides were reviewed for all cases. All cases met the histologic criteria for anaplastic carcinoma, as defined by the World Health Organization classification. 8 These criteria include the four basic histologic subtypes: spindle cell, giant cell, pleomorphic giant cell, and round cell. Tumors were classified regarding the main cellular component. The number of giant cells present was semiquantitatively evaluated and separated into three groups: occasional (1/5 high power field), frequent (2-9/5 high power field), and abundant (Ͼ10/5 high power field).
Formalin-fixed, paraffin-embedded sections were stained with periodic acid-Schiff (with and without diastase digestion) and Mayer's mucicarmine. Immunophenotypic analysis was performed in 30 cases with suitable material according to the standardized avidin-biotin method of Hsu et al. 9 Not all studies were performed on each case and, when limited, the epithelial markers were applied preferentially to document epithelial origin of the tumor cells. The broad, commercially available antibody panel is given in Table 1 . Predigestion was performed for 3 minutes with 0.05% proteinase (Protease VIII; Sigma Chemical Co, St Louis, MO) in a 0.1 mol/L phosphate buffer at a pH of 7.8 at 37°C. Antigen enhancement (recovery) was performed by using formalinfixed, paraffin-embedded tissue treated with a buffered citric acid solution and then heated for 20 minutes in a calibrated microwave oven. Following this, the sections were allowed to cool at room temperature in a citric acid buffer solution for 45 minutes before continuing the procedure. 10 Appropriate positive and negative controls were used throughout.
A positive immunoreaction was determined by chromogen deposition within the cytoplasm of the tumor cells, whereas a positive reaction with the cell cycle markers was determined by the depositing of chromogen within the nucleus. Antibody reactions were graded as weak (1ϩ), moderate (2ϩ), or strong (3ϩ) staining, and the fraction of positive cells was determined by separating the percentage of positive cells into four groups: less than 10%, 10% to 50%, 51% to 90%, and greater than 90%.
Point mutations in K-ras-2 were sought in 12 cases with sufficient and suitable material on which to perform the study. Mutational analysis was performed by topographic microdissection to yield 800 to 1,200 cells per analyte with polymerase chain reaction amplification for the K-ras-2 exon 1 gene, flanking intron primers were used as previously described. [11] [12] [13] Cycle sequencing with 35 S was performed by use of di-deoxy terminators and one of the amplifying primers and subsequently run on a 6% denaturing polyacrylamide gel. Suspect mutations were subsequently reamplified and sequenced by use of a different primer.
Categorical variables were analyzed using chi-square tests to compare observed and expected frequency distributions. Fisher's Exact Test was used as a substitute for the chi-square test when numbers were fewer than five patients. Comparison of means between groups were made with unpaired t-tests or one-way analysis of variance, depending on whether there were two groups or more than two groups, respectively. Multiple comparisons were analyzed using the Tukey method. Confidence intervals of 95% were generated for all positive findings. The alpha level was set at P Ͻ .05. All analysis was conducted using Statistical Package for the Social Sciences 8.0 for PC (Chicago, IL).
Results

Clinical
The patients included 10 women and 25 men, with a male:female ratio of 2.5:1 ( Table 2 ). Ages ranged from 34 to 85 years, with an average age at presentation of 62.5 years (median, 62 years). Twenty-six patients were white, three were black, one was Asian, and the race was unknown in five patients. Patients experienced weight loss (n ϭ 17), abdominal pain, or discomfort, frequently in the right upper quadrant or epigastrium (n ϭ 18), loss of appetite (n ϭ 5), nausea and/or vomiting (n ϭ 4); fatigue (n ϭ 2); and diarrhea (n ϭ 2). Four patients each presented with a palpable mass and with jaundice. The duration of symptoms ranged from 3 days to 1 year, with an average of 13.2 weeks. The clinical presentation did not have a bearing on the outcome of the patient (P ϭ .387). On average, there was a much shorter duration of symptoms for patients with tumors with a dominant spindle cell component (6 weeks) when compared with the average for patients with tumors with pleomorphic large cells (14.1 weeks), but this difference is not statistically significant.
Radiographic Investigation
Roentgenographic procedures were performed in the majority of patients, with computer tomography and ultrasound the most frequently used. Cross-sectional images identified a diffuse enlargement of the pancreas, or a mass involving the pancreas. Erosion of the organ margins or obliteration of the fat planes suggested a malignant diagnosis. Degenerative changes could be identified in many of the tumors. 
Pathology
Macroscopic. The majority of tumors (n ϭ 17) were located in the head of the pancreas (Table 3 ). An additional three occurred in the body, 10 in the tail, two in both the body and tail, and three involved the entire pancreas. Tumor size ranged from 2.5 to 20 cm, with an average size of 9.2 cm. While the pleomorphic subtype tended to be larger on average (pleomorphic, 9.8 cm; spindle cell, 4.9 cm), there was no statistically significant difference between these subtypes of anaplastic carcinoma based on size, nor was there a worse clinical outcome (P ϭ .170). The tumors were firm to rubbery (n ϭ 21), soft to fleshy (n ϭ 5), or cystic (n ϭ 8). The cystic cavities were filled with opaque, brown, hemorrhagic, thick material. Ten tumors yielded macroscopically visible necrotic debris, while an additional 10 cases showed old blood when the tumors were serially sectioned. The surrounding pancreatic tissue was generally atrophic.
Microscopic. The tumors were composed of an assortment of growth patterns and cell types interspersed between one another. Even though there was a remarkable heterogeneity within each specific subtype of anaplastic carcinoma, in aggregate a single cell type predominated (each of these subtypes will be described in detail below). All the tumors were widely invasive, infiltrating into the surrounding pancreatic parenchyma and extrapancreatic soft tissues, as well as being identified around nerves (perineural invasion) and within vascular and lymphatic channels. Direct extension of the tumor into surrounding organs was documented in 16 tumors (duodenum, 7; adrenal, 2; spleen, 4; hepatic porta, stomach, and kidney; 1 each). Furthermore, 20 cases showed metastatic disease (systemic metastases, 15; lymph nodes, 14).
The liver (n ϭ 13) and lungs (n ϭ 10) were affected by metastatic disease most frequently, followed by peritoneum (n ϭ 7), adrenals (n ϭ 5), and heart, spleen, brain, vertebral, pleural, thyroid (1 each).
Large-Cell Type (n ‫؍‬ 31). The cells were arranged in nests, made up of discohesive, large, pleomorphic cells without any significant background stroma (Fig 1, top) . The tumor cells were large, round to polygonal, frequently irregular in shape, with abundant eosinophilic cytoplasm ( Fig  1A) . Focal spindling (10% to 30%) of the tumor cells was observed in 11 tumors. Rare, isolated, osteoclastic-type giant cells were noted in five tumors. The majority of cases (n ϭ 22) contained multinucleated giant cells, either of foreign body type (peripheral nuclei) or tumor giant cells (centrally placed atypical nuclei). Furthermore, phagocytic activity was common (n ϭ 22) (Fig 1, bottom) . Malignant giant cells had engulfed other tumor cells (cannibalism) and/or inflammatory cells (Fig  1B) , while the foreign body giant cells tended to engulf tumor cell or inflammatory cell breakdown products. Two cases showed areas of squamous differentiation. The origin of these anaplastic cells (pleomorphic cells) from an epithelial primordia was partially supported by the presence of infiltrating ductal adenocarcinoma at the periphery of the tumor mass (n ϭ 12). The production of mucin by the anaplastic tumor cells was confirmed with a positive mucicarmine reaction in 10 of 31 cases tested. Chronic pancreatitis could be identified in the uninvolved surrounding pancreas in nine cases.
Spindle-Cell Type (n ‫؍‬ 4). These tumors were composed largely of spindle cells arranged in a loose storiform pattern. These tumor cells were more monotonous and uniform than those of the large-cell type, but still had a degree of variation in shape and size (Fig 2) . Tumor giant cells and squamous metaplasia were identified in one tumor each. One of the cases contained an infiltrating ductal adenocarcinoma (documented by the presence of gland profiles and mucin production).
Immunohistochemistry
Eighteen of the tumors tested (n ϭ 23) were reactive with at least one epithelial marker (Table  4 ; Fig 3, top) , coexpressing vimentin in 15 cases (Fig 3, bottom) . Dupan 2, CA19-9, and carcinoem- bryonic antigen were variably reactive. CD68 (KP-1) was reactive in tumor giant cells in two cases. p53 was moderately to strongly reactive in a limited number of cells in the majority of cases tested (n ϭ 10/14). Reactivity with p27 equaled or exceeded the reactivity of cyclin E in all positive cases, except for one case (nonreactive with p27; reactive with cyclin E). There was no reactivity with CK20, B72.3, chromogranin, synaptophysin, or smooth muscle actin. Because a limited number of slides were available, keratin and vimentin were the only immunohistochemical studies performed in the three patients who were alive without evidence of disease.
Furthermore, the three patients who had died without evidence of disease also had immunoreactivity with keratin, DUPAN2, and vimentin, but other markers were nonreactive or there was insufficient material on which to perform the tests.
K-ras-2 Oncogene Determination
Eight of the 12 tumors tested for K-ras-2 oncogene showed a mutation, while the remaining four patients did not show a mutation and were of wild type. All the mutations were glycine to valine on codon 12, chromosome 12p. The eight mutated cases occurred in patients with both large cell type (n ϭ 7) and spindle cell type (n ϭ 1), all of whom died with an average survival of 1.9 and 1 month, respectively. Mean overall survival for the patients with K-ras mutations was 1.7 months. All of the patients with wild type (n ϭ 4) had large cell histomorphology and died with disease after an average survival of 9.5 months. The difference in survival between patients with and without K-ras oncogene mutations was not statistically significant (P ϭ .173).
Clinical Outcome
Follow-up information was available in all 35 patients (Table 5 ). Three patients were alive at last follow-up, two without evidence of disease (14.6 and 7.2 years, respectively), and one with recurrent tumor (follow-up 14.7 years), all with the large cell type. Three patients, all with large cell type, had died without evidence of disease of unrelated causes after an average survival of 4.7 years.
The remaining 29 patients died with disseminated tumor (average, 5.5 months). Patients with the large cell type had a slightly longer survival (6.0 months) when compared with patients with the spindle cell type (3.3 months). While this difference was statistically significant, the difference is not clinically significant. As previously stated, there was no statistically significant difference in survival based on K-ras oncogene mutation.
There was no statistically significant difference in outcome between sites of metastatic disease (P ϭ .778), tumor type (P ϭ .559), squamous metaplasia (n ϭ 3; P ϭ .690), infiltrating adenocarcinoma (n ϭ 13; P ϭ .634), or chronic pancreatitis (n ϭ 11; P ϭ .480). Patients who had tumors with abundant giant cells tended to have a longer survival (16.4 months) than patients with frequent (8.0 months) or occasional giant cells (5.4 months). While these differences are statistically significant (P ϭ .011), it is probably not clinically significant with such a short overall survival.
Discussion
Anaplastic carcinomas of the pancreas are infrequent tumors, accounting for less than 10% of all pancreatic tumors. [1] [2] [3] [4] [5] [6] A number of terms have been applied to these tumors, including pleomorphic carcinoma, pleomorphic giant cell carcinoma, pleomorphic large cell carcinoma, sarcomatoid carcinoma, and small cell carcinomas 14, 15 Anaplastic foci are identified in ductal adenocarcinomas 5 and in ectopic pancreata, but are not the dominant pattern of growth. 16 Although a variety of patterns can be present within each tumor, Alguacil-Garcia and Weiland mingled with occasional eosinophilic plump cells and giant cells). Osteoclastic giant-cell type is classified by the World Health Organization as a separate entity and were not considered in this discussion. We believe that small, round-cell tumors 14, 17, 18 of the pancreas are secondary lesions with multifocal tumor masses, usually metastatic small cell carcinomas of the lung, malignant lymphomas, or primary endocrine tumors. This assertion is further supported by the literature, in which pulmonary primaries are not excluded 19, 20 or islet cell tumors are confirmed. 21 Anaplastic carcinomas do not preferentially involve a specific part of the pancreas, even though we had more cases present in the head of the pancreas, this difference was not statistically significant (Table 3) . These findings are different from the literature, [5] [6] [7] 22 although in agreement with Guillan and McMahon. 23 Cyst formation occurred within nine of the tumors in our series, a finding that has been previously described. 24, 25 Furthermore, cystic tumors (mucinous cystic neoplasm) can have associated anaplastic carcinoma. [26] [27] [28] [29] [30] All tumors show hemorrhage and/or necrosis. 15 Fundamental to the diagnosis of anaplastic carcinoma are the large, bizarre, frequently multinucleated malignant cells, containing abundant, eosinophilic cytoplasm and lacking a supporting stroma. 1, 15, 31 The "giant cells" are malignant tumor cells, although osteoclast-type giant cells also can be present, as our study suggests. 25 The presence alone of osteoclast-type giant cells does not represent a malignant finding, as they may occur in a variety of benign conditions (eg, abscesses, hemorrhage, necrosis, pseudocysts, fungal infections, and sarcoidosis). 32, 33 The various types of giant cells may be related, 34 arise from a multipotential stem cell, 32 or represent a "sarcomatous metaplasia" of the carcinoma cells. 5, [35] [36] [37] [38] [39] [40] [41] [42] [43] The frequent expression in our series of malignant giant cells for CK7 seems to supports an epithelial origin 3, 7, [36] [37] [38] [39] 44 or dedifferentiation of a ductal adenocarcinoma, rather than an acinar differentiation, 45 especially in light of the associated ductal adenocarcinoma. 5, 7, 8, 22, 36, 37, [39] [40] [41] 46 Phagocytosis of erythrocytes or tumor cells (cannibalism) is a common feature in all anaplastic carcinomas. 2, 5, 7, 22, 31, 37, 47, 48 The tumor giant cells must be distinguished from reactive histiocytes and foreign body giant cells, as well as the cells of metastatic carcinoma, malignant melanoma, choriocarcinoma, Hodgkin's 
Abbreviation: N/A, not applicable. * Thirty cases had immunophenotypic analysis performed, although not all antibodies were used in each case, with only a single antibody tested in a few cases because of limited archival material.
† Fifteen vimentin-positive tumors coexpressed keratin (n ϭ 12), CK7 (n ϭ 7), or CAM 5.2 (n ϭ 6).
‡ Reactivity with p27 equaled or exceeded the reactivity with cyclin E in all positive cases.
lymphoma, anaplastic large cell lymphoma, epithelioid sarcomas, and malignant fibrous histiocytoma. 6, 7, 33, 49 An immunohistochemical evaluation can assist in distinguishing cells of anaplastic carcinoma of the pancreas from the tumors listed above. In our series, tumor cells were usually reactive with at least one epithelial marker (EMA, CK7, cytokeratin cocktail; n ϭ 18/23), supporting the studies in the literature, 22,24 while also coexpressing vimentin. 28, 30, 34, 35, 37, [39] [40] [41] [42] [50] [51] [52] [53] [54] [55] [56] The presence of infiltrating ductal adenocarcinoma in the cases that did not have blocks on which to perform the immunohistochemical analyses was deemed as support of an epithelial origin for the anaplastic carcinoma, although we were not able to completely exclude a malignant lymphoma (anaplastic large cell type) or a malignant melanoma.
Our detected K-ras mutation rates (66.7%) were in the range of those reported in the literature for anaplastic carcinoma. 32, 38, 39, 47, 53, 57 K-ras mutations are identified in a high percentage of pancreatic cancers (reported up to 100% 58 ), usually increasing in frequency with greater cytologic atypia, which is suggested to affect early pancreatic carcinogenesis, resulting in a dismal prognosis. [11] [12] [13] [59] [60] [61] [62] [63] [64] The findings in our series support a poor prognosis and a relatively shorter survival (1.7 months) in patients with a K-ras mutation than those without (9.5 months). However, this finding is not statistically significant, and this small difference of a few months is not clinically germane.
We tried to evaluate the prognostic role of the cell cycle regulatory proteins, cyclin E and p27. While tumor development and growth regulation is not well understood, cyclin E and p27 play an important role in cell cycle regulation. Cyclins (proteins) regulate the activity of cyclin-dependent kinases (CDK), which are active only when bound to cyclins. 65, 66 Cyclin-CDK complexes propel the cell into S phase or mitosis, depending on their specificity. The major cyclin groups (G1 cyclins A, D, and E, and G2 cyclins A and B) affect proliferation depending on the phase of the cell cycle affected. G1 cyclins bind to CDK in the G1 phase and are required for entering the S phase. G2 cyclins are necessary for entering the M phase. 65, 66 Cyclin E acts at the G1-S transition, with p27 counteracting the effects of cyclin E, because it is a stoichiometric inhibitor of the cyclin-CDK complex (along with p15) in the G1 phase.
67,68
High cyclin E and low p27 levels are associated with a significant increase in mortality in breast cancer patients, although each marker is considered an independent prognostic marker. [69] [70] [71] Similarly, a lack of p27 expression is associated with a worse prognosis in colorectal and gastric carcinomas. 72, 73 Unfortunately, all our cases showed a weak reactivity with both antibodies (except for one case), which did not yield a specific relationship to histologic subtype or clinical outcome.
Similar to the K-ras mutation results, there is variable detection of p53 protein mutations in anaplastic carcinomas. 57, 74, 75 It has been proposed that K-ras mutations may exceed the frequency of p53 mutations in pancreatic cancer in general. 57, 74, 76 However, in contrast to these findings, we identified the presence of presumed p53 mutations in 10 of 14 cases tested, with less than 10% to more than 90% of the tumor cells showing the abnormal phenotype by immunohistochemistry, with most showing 2ϩ to 3ϩ reactivity (Table 4 ). This finding may support the assertion in the literature that suggests a worse prognosis associated with p53 protein abnormalities. 58, [75] [76] [77] [78] [79] The patients in our series, in order of frequency, showed metastatic disease to liver, lung, and peritoneum, irrespective of the anatomic region of the pancreas affected by the primary tumor. Our results are different from the literature, which states that body and tail tumors are more likely to give pulmonary rather than hepatic metastases, 41 and that the incidence of pulmonary metastases is higher in anaplastic carcinoma than in conventional ductal adenocarcinoma. 5, 6, 40 In our cases, direct spread to the surrounding soft tissues, stomach, spleen, and peritoneum was similar to those reported in the literature. 6, 80 While infrequent, metastatic deposits were occasionally better differentiated than the primary tumor.
The prognosis for anaplastic carcinoma, both subtypes considered, is worse than the average survival of patients with invasive ductal adenocarcinoma, not further specified of 10 to 20 months, with less than 3% 3-year survival. 22, 40, 41, 81 Although the number of months is not significantly different statistically, nor perhaps clinically important, individual tumor subtypes may have a limited difference in patient survival. With so few cases and a limitation in statistical analysis, we cannot be certain that the pleomorphic large cell type has a better prognosis than the spindle cell type, even though we have more cases than reported in the literature. 15, 33, 43, 51 Overall tumor size is not a reliable prognostic indicator. 82 In summary, anaplastic carcinomas of the pancreas generally occur with greater frequency in the head of the pancreas, usually in older men. The epithelial nature and ductal origin of the tumors can usually be confirmed by immunohistochemical studies and the frequent and strong association with infiltrating ductal adenocarcinoma. Prognostic markers and K-ras oncogene mutations support a proliferative tumor that has a poor prognosis irrespective of the various subtypes of large cell, osteoclastic giant cell, or spindle cell type. Irrespective of the treatment, the overall prognosis for this tumor remains grave.
